Why the study?
Does metallothionein overexpression prevent diabetes-induced contractility and Ca2+ handling deficits in cardiomyocytes by reducing ROS production?
Population
Individual cardiomyocytes isolated from control hearts, diabetic OVE26 hearts, and diabetic hearts…
Comparison
Overexpression of antioxidant protein… vs Diabetic OVE26 cardiomyocytes without MT…
Design
Preclinical
Authors
Loading...
MT overexpression may protect diabetic cardiomyocytes from ROS damage; leaves open translation to in vivo or human therapies.
Does metallothionein overexpression prevent diabetes-induced contractility and Ca2+ handling deficits in cardiomyocytes by reducing ROS production?
Metallothionein overexpression prevents diabetes-induced cardiomyocyte damage by inhibiting ROS production via angiotensin II and flavoprotein enzyme-dependent pathways.
Ye et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: